Expanded Label News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Expanded label. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Expanded Label Today - Breaking & Trending Today
Third-Quarter 2022 Results: Net Sales of $925.4 Million GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones ....
Expanded Entresto Label Makes 1.8 Million More HF Patients Eligible medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
(1) BASEL (dpa-AFX) - Today s Daily Dose brings you news about temporary suspension of bluebird bio s gene therapy trials in sickle cell disease, Sesen Bio s regulatory catalyst for this year, partial hold on Cortexyme s open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer s disease, and expanded FDA approval of Novartis Entresto. Read on. 1. Sickle Cell Disease Trial Blues For bluebird bio Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company s LentiGlobin gene therapy trials for sickle cell disease were temporarily suspended after two cases of cancer were reported in study participants. ....
BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGN s Libtayo Gets FDA Nod Read on. 1. Bio-Path On A Steady Path Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells. In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib, on February 23, 2021. Prexigebersen is in a Phase 2 study for blood cancers and Prexigebersen-A, a drug product modification of Prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. ....